Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YIAD-0205, an orally administered inhibitor of Aβ(1-42) aggregation, has exhibited in vivo efficacy in a 5XFAD transgenic mouse model that harbors five familial AD mutations [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | YIAD-0205, an orally administered inhibitor of Aβ(1-42) aggregation, has exhibited in vivo efficacy in a 5XFAD transgenic mouse model that harbors five familial AD mutations [1]. |
In vitro | YIAD-0205, at concentrations of 10 and 100 μM, inhibits the aggregation of Aβ (1-42) [1]. |
In vivo | YIAD-0205 (50 mg/kg; oral administration; biweekly for one month) was effective in reducing levels of Aβ plaques and Aβ oligomers in the 5XFAD mouse model aged at 6.0 months [1]. |
Molecular Weight | 565.69 |
Formula | C26H16Br2ClN3 |
CAS No. | 2446054-34-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
YIAD-0205 2446054-34-6 inhibitor inhibit